JESUS MIGUEL
UNDA URZAIZ
Investigador/a en el periodo 2002-2023
Hospital de Gran Canaria Dr. Negrin
Las Palmas de Gran Canaria, EspañaPublicaciones en colaboración con investigadoras/es de Hospital de Gran Canaria Dr. Negrin (7)
2019
-
Safety of nivolumab in metastatic renal cell carcinoma patients: A real-life experience in a Spanish urology setting
Actas Urologicas Espanolas, Vol. 43, Núm. 7, pp. 364-370
2015
-
Sequential combination of mitomycin C plus bacillus calmette-guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: Final outcome of CUETO 93009, a randomized prospective trial
European Urology, Vol. 67, Núm. 3, pp. 508-516
2013
-
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
British Journal of Cancer, Vol. 109, Núm. 1, pp. 121-130
-
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572
2011
2009
-
Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model
Journal of Urology, Vol. 182, Núm. 5, pp. 2195-2203
2008
-
Prognostic Factors in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials
European Urology, Vol. 53, Núm. 5, pp. 992-1002